Is your practice out of COVID-19 tests? Here’s what you need to know.
By Alison Adduono, Director of Marketing Communications
This past summer, you may not have thought much about COVID-19 or your testing supplies, correct? If anything, you may have thought it was in your rearview mirror. In the wake of this latest surge (see CDC data), you may now be reaching for your supply shelf and realizing you need to restock COVID tests. Well, if you are a former Accula™ user you may be in for a shock.
On April 11, 2023, Thermo Fisher Scientific announced it would discontinue the manufacturing and direct sales of the Thermo Fisher Accula™ line of products by April 26, 2023, making it available only through distribution. According to reports in the marketplace, many are finding that they have completely run out. The affected products are:
Accula™ Dock
Accula™ SARS-CoV-2 Test and Control Kit
Accula™ Flu A/Flu B Test and Control Kit
If this is the case, you're probably scrambling to find another point-of-care molecular test in its place. Anavasi Diagnostics has just the solution for you. Our AscencioDx system is the best Accula replacement. Not only is it reliable, highly precise, but it is also very affordable.
COVID-19 nasal swab collection
Photo Credit: iStock by Getty Images
How Does AscencioDx® Measure Up to Accula™?
The AscencioDx® demonstrates comparable proficiency to the Accula™ in terms of its technological advancements, benefits, and cost-effectiveness. Both systems employ reverse transcription (RT) in-vitro amplification methods to generate thousands of copies and are classified as Nucleic Acid Amplification Tests (NAATs). While the Accula™ operates as an RT-PCR platform, undergoing multiple heating and cooling cycles to amplify the target, the AscencioDx® adopts the RT-LAMP method. This approach utilizes a singular heating phase combined with sophisticated biochemistry to achieve similar detection. It's worth noting that RT-LAMP (reverse transcription loop-mediated isothermal amplification) represents a more recent technological advancement, emphasizing advanced probes and primers for enhanced efficiency and speed.
The patent-pending design of our Ascencio system has built-in target redundancy detecting three (3) distinct regions of the SARS-CoV-2 viral genome, making it very robust against mutation on any single n-gene location. In genomic sequence testing, The AscencioDx COVID-19 Test assay covers 99.99% of all current known variants and sub-variants such as Omicron, Eris (EG.5), Fornax (FL.1.5.1) and the newest Pirola (BA.2.86). For added assurance, the detector includes an internal control on every test sample to confirm test function.
AscencioDx Benefits:
Positive results in as little as 20 minutes, and most negative results in about 30 minutes
Less than 2 minutes of hands-on time required to set up the test
Uses lower nasal swab samples, making it easier to collect a sample specimen
Low-cost reusable molecular detector good for > 4,000 uses
In addition to its affordability and ease of use, the AscencioDx system also includes a value-added benefit at no extra charge. Anavasi Diagnostics has developed a unique detector portal to help you manage, store, and report patient test results. This system not only provides customizable report templates and one-step features, but it also reduces your data entry by populating patient data with the scan of a driver’s license. Utilizing a scannable QR code to transmit test results, the detectors are secure – no Bluetooth or apps required.
For more information on The AscencioDx COVID-19 Test and The AscencioDx Molecular Detector please visit www.anavasidx.com or contact us at sales@anavasidx.com.
For a limited time, Anavasi Diagnostics will be offering an introductory package as well as a swap out program for existing Accula™ users. Contact us today for more details.
Resources:
Where Speed, Efficiency, & Accuracy Align
The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector have not been FDA cleared or approved, but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
